Workflow
JW THERAP(02126)
icon
Search documents
药明巨诺-B盘中涨近7% CAR-T产品集体通过专家评审 公司积极准备医保申报工作
Zhi Tong Cai Jing· 2025-09-29 07:44
消息面上,国家医保局近日公告,2025年国家基本医保目录及商保创新药目录调整专家评审工作已结 束,包括药明巨诺的倍诺达在内的5款CAR-T药物均通过了专家评审。据悉,CAR-T治疗由于"一针超百 万元"的高昂定价始终未能进入基本医保目录。截至目前,CAR-T疗法已经基本形成了以商业医疗保险 为主体、特病特药保险为补充、金融分期及各类救助方案为辅的多元支付格局。 药明巨诺-B(02126)盘中涨近7%,截至发稿,涨6.1%,报4.35港元,成交额728.67万港元。 公开资料显示,药明巨诺的倍诺达已被70余款商业医疗险产品纳入,公司也对外回应称,公司CAR-T产 品会积极参加2025年医保和商保创新药目录申报工作。业内人士普遍认为,此次5款CAR-T产品集体通 过专家评审,释放出积极信号,显示监管层在提高前沿疗法可及性上的决心。 ...
港股异动 | 药明巨诺-B(02126)盘中涨近7% CAR-T产品集体通过专家评审 公司积极准备医保申报工作
智通财经网· 2025-09-29 07:42
智通财经APP获悉,药明巨诺-B(02126)盘中涨近7%,截至发稿,涨6.1%,报4.35港元,成交额728.67万 港元。 消息面上,国家医保局近日公告,2025年国家基本医保目录及商保创新药目录调整专家评审工作已结 束,包括药明巨诺的倍诺达在内的5款CAR-T药物均通过了专家评审。据悉,CAR-T治疗由于"一针超百 万元"的高昂定价始终未能进入基本医保目录。截至目前,CAR-T疗法已经基本形成了以商业医疗保险 为主体、特病特药保险为补充、金融分期及各类救助方案为辅的多元支付格局。 公开资料显示,药明巨诺的倍诺达已被70余款商业医疗险产品纳入,公司也对外回应称,公司CAR-T产 品会积极参加2025年医保和商保创新药目录申报工作。业内人士普遍认为,此次5款CAR-T产品集体通 过专家评审,释放出积极信号,显示监管层在提高前沿疗法可及性上的决心。 ...
药明巨诺(02126) - 2025 - 中期财报
2025-09-25 08:50
股份代號:2126 (於開曼群島註冊成立的有限公司) JW (Cayman) Therapeutics Co. Ltd * 2025 中期報告 * * Stock Code: 2126 (Incorporated in the Cayman Islands with limited liability) JW (Cayman) Therapeutics Co. Ltd * 2025 INTERIM REPORT JW (Cayman) Therapeutics Co. Lt * d INTERIM REPORT 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 業務摘要 | 7 | | 管理層討論與分析 | 10 | | 企業管治及其他資料 | 28 | | 簡明綜合損益及其他全面收入表 | 50 | | 簡明綜合財務狀況表 | 51 | | 簡明綜合權益變動表 | 53 | | 簡明綜合現金流量表 | 54 | | 簡明綜合財務報表附註 | 55 | | 釋義及技術詞彙 | 75 | 公司資料 董事會 執行董事 劉敏先生 (主席) (1) 非執行董 ...
药明巨诺-B午后涨超7% 首版商保创新药目录完成专家评审 5款CAR-T药物均过评
Zhi Tong Cai Jing· 2025-09-25 06:24
Core Viewpoint - The approval of five CAR-T products, including WuXi AppTec's Benauda, by the National Healthcare Security Administration (NHSA) is seen as a positive signal indicating the regulatory body's commitment to improving access to cutting-edge therapies [1] Group 1: Company Specifics - WuXi AppTec's stock price increased by over 7% in the afternoon session, reaching 4.22 HKD with a trading volume of 19.47 million HKD [1] - The company's CAR-T product, Benauda, has been included in over 70 commercial health insurance products, indicating strong market acceptance [1] - WuXi AppTec has stated that it will actively participate in the application process for the 2025 National Basic Medical Insurance and commercial insurance innovative drug directories [1] Group 2: Industry Insights - The recent approval of CAR-T therapies reflects a shift towards a multi-faceted payment structure, primarily driven by commercial health insurance, supplemented by special disease insurance and various financial assistance programs [1] - Despite the high cost of CAR-T treatments, which can exceed one million yuan per injection, the industry is adapting to ensure broader access through innovative insurance solutions [1]
港股异动 | 药明巨诺-B(02126)午后涨超7% 首版商保创新药目录完成专家评审 5款CAR-T药物均过评
智通财经网· 2025-09-25 06:21
Core Viewpoint - WuXi AppTec's stock price increased by over 7% following the announcement that five CAR-T therapies, including its product Benodda, passed expert review for inclusion in the 2025 National Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory, indicating a positive regulatory signal for advanced therapies [1] Group 1: Company Performance - WuXi AppTec's stock price rose by 5.76% to HKD 4.22, with a trading volume of HKD 19.47 million [1] - The company is actively participating in the application process for the 2025 medical insurance and commercial insurance innovative drug directories [1] Group 2: Industry Insights - The approval of five CAR-T products, including WuXi AppTec's Benodda, reflects a commitment from regulators to enhance the accessibility of cutting-edge therapies [1] - CAR-T therapies have not yet entered the basic medical insurance directory due to their high costs, often exceeding one million yuan per treatment [1] - The current payment structure for CAR-T therapies is diverse, primarily relying on commercial health insurance, supplemented by special disease insurance, financial installment plans, and various assistance programs [1]
药明巨诺-B(02126.HK)授出合共420.4万份购股权
Ge Long Hui· 2025-09-16 14:28
Group 1 - The company WuXi AppTec (02126.HK) announced the grant of a total of 4,204,490 stock options to its Chairman, CEO, and Executive Director Liu Min on September 16, 2025, in accordance with the incentive plan adopted after its initial public offering on October 14, 2020 [1]
药明巨诺-B(02126)授出合共420.45万份购股权
智通财经网· 2025-09-16 14:27
Group 1 - WuXi AppTec (02126) announced the grant of a total of 4.2045 million stock options to its Chairman, CEO, and Executive Director, Mr. Min Liu, on September 16, 2025, in accordance with the terms of the incentive plan adopted after its initial public offering on October 14, 2020 [1]
药明巨诺-B授出合共420.45万份购股权
Zhi Tong Cai Jing· 2025-09-16 14:27
Group 1 - WuXi AppTec (02126) announced the grant of a total of 4.2045 million stock options to Mr. Liu Min, the Chairman, CEO, and Executive Director of the company, on September 16, 2025 [1] - The stock options were granted under the terms of the incentive plan adopted after the company's initial public offering on October 14, 2020 [1]
药明巨诺(02126) - 授出购股权
2025-09-16 14:20
JW (Cayman) Therapeutics Co. Ltd 藥明巨諾(開曼)有限公司* (於開曼群島註冊成立的有限公司) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 (股份代號:2126) 授出購股權 本 公 告 由 藥 明 巨 諾(開 曼)有 限 公 司(「本公司」,連 同 其 附 屬 公 司 統 稱「本 集 團」)根據香港聯合交易所有限公司(「聯交所」)證券上市規則(「上市規則」)第 17.06A、17.06B及17.06C條作出。 本公司董事(「董事」)會(「董事會」)宣佈,於2025年9月16日,根據2020年10月14 日採納的本公司首次公開發售後激勵計劃(「首次公開發售後激勵計劃」)的條 款將合共4,204,490份購股權(「購股權」)授予本公司主席、行政總裁兼執行董事 劉敏先生(「劉先生」)。 上市規則的涵義 由於向劉先生授予購股權會導致劉先生於直至授出日期(包括該日)止12個月 期間內獲授的所有購股權及受限制股份單位(「受限 ...
目瞪口呆!一天暴涨120%!
天天基金网· 2025-09-12 08:32
Market Overview - The A-share market experienced slight fluctuations, with the Shanghai Composite Index closing down by 0.12%, the Shenzhen Component Index down by 0.43%, and the ChiNext Index down by 1.09% [5] - A total of 1,926 stocks rose, while 3,373 stocks fell, indicating a challenging market environment [6] Stock Performance - The total trading volume reached 25,483.12 billion, with a total of 5,429 stocks traded [7] - Notable sectors included the storage chip sector, which saw significant gains, with companies like Jingzhida and Demingli hitting the daily limit [8] - The storage product prices are expected to rise by 20% to 30%, following a previous announcement of a 10% increase by SanDisk [8] Sector Highlights - The non-ferrous metals sector showed strength, with companies like Northern Copper and Shengda Resources also hitting the daily limit [10] - Real estate stocks saw a surge, with Rongsheng Development and Huaxia Happiness reaching their daily limit [12] Financial Sector - The financial sector faced declines, with major banks like Pudong Development Bank and China Merchants Bank seeing drops of over 3% [13][12] - Securities firms also experienced downturns, with Guohai Securities and Dongfang Securities both declining [14] Hong Kong Market - The Hong Kong stock market saw a rise, with major indices increasing by over 1% [15] - Alibaba's stock surged by 5.37%, attributed to the introduction of self-developed chips for AI model training [16] - Evergrande Property experienced a significant increase of over 23% due to potential acquisition interest [16] Notable Company Developments - Yaojie Ankang's stock price skyrocketed by over 120% following the announcement of clinical trial approval for its core product [19]